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Introduction: This study describes the experience of a tertiary care hospital in the management of
differentiated thyroid cancer. Thyroid cancer accounts for less than 1% of all human malignancy.
Nevertheless, it is the commonest endocrine malignancy constituting 90% of endocrine cancers. It is the
commonest cancer in Saudi Arabian women second to breast cancer. This fact makes differentiated
thyroid cancer an important tumor and a challenging disease.
Methods: The medical records of patients diagnosed to have differentiated thyroid cancer in King Faisal
Specialist Hospital and Research Centre, Jeddah, Saudi Arabia between 1st January 2000 and 30th
September 2006 were reviewed retrospectively. The data included patient’s demographic details, clinical
diagnoses, co-morbid conditions, relevant investigations, imaging studies, medical and surgical treat-
ment offered, types of surgeries performed, radioactive iodine therapy given, and the complications and
outcome of management. Management of these patients follows a clinical care pathway set up by the
hospital Thyroid Cancer Group representing various multidisciplinary team members.
Results: One hundred and eight medical records were reviewed. Of these, 72 (66.7%) patients were
females and 36 (33.3%) were males. Median age for the females was 40 years, and for males 45 years.
Ninety patients (83.3%) had a papillary carcinoma, four patients (3.7%) had a follicular carcinoma and
fourteen patients (13%) had other types, namely medullary thyroid carcinoma, anaplastic carcinoma and
lymphoma. A total of 78 patients underwent various forms of surgery in our hospital and the remaining
patients underwent operation in the district hospitals before they were referred to our centre for further
management. Complications included bleeding (1.8%), voice changes (4.5%), and hypocalcaemia (3.8%).
The overall outcome showed that 99 patients (91.7%) were alive and well at the time of analysis,
4 patients (3.7%) died and 5 patients (4.6%) were lost to follow up.
Conclusions: This hospital-based epidemiological study, the largest one done in the western part of Saudi
Arabia, showed that differentiated thyroid cancer behavior and the management approach we adopt is
not different from other centres of excellence. In spite of the relatively higher number of redo surgery we
performed in these patients, yet the incidence of recurrent laryngeal nerve injury and hypocalcaemia are
similar to what is published in the literature.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Thyroid cancer (TC) is a heterogonous group of diseases with
different tumor behavior and tumor biology. It includes differenti-
ated thyroid cancer (DTC), medullary thyroid carcinoma, anaplastic
carcinoma, thyroid lymphoma and rarely secondary deposits from
other tumors. TCis the most common malignancy of the endocrine
system as it accounts for 90% of all endocrine malignancies. Its
incidence has been increasing over the past 20 years.1 DTC is thedi).
ciates Ltd. Published by Elsevier Ltmost common thyroid malignancy that includes the major types,
papillary carcinoma, follicular variant, Hurthle cell carcinoma as
well as rare subtypes. Several classiﬁcations and staging systems
have been proposed for DTC. However, no clear consensus has
emerged so far favoring any one over the other. as a prognostic
scoring system developed in one particular group of patients has
often performed poorly when applied to other groups of patients
with the same disease.
For the United States population the life time risk of being
diagnosed with DTC is about 1% (0.84% for women and 0.30% for
men) and with the incidence increasing by 6.2% per year, thyroid
cancer is currently the 8th common malignancy diagnosed in
women in the United States of America.2e4 Although it can occur atd. All rights reserved.
Table 1
Pathological types, number and percentage of thyroid carcinoma by gender at
KFSH&R-J, January 2000 to September 2006.
Type of tumor Sex Total
Female Male
Papillary 62 (57.4%) 28 (25.92%) 90(83.3%)
Follicular 3 (2.8%) 1 (0.93%) 4 (3.7%)
Others 7 (6.5%) 7 (6.5%) 14 (13.0%)
Total 72 (66.7%) 36 (33.3%) 108 (100%)
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65e69 years inmen.5 Among patients aged 15e24 years of age, DTC
accounts for 7.5e10% of all diagnosed malignancies.6 Despite that it
occurs commonly in women yet the mortality rates are higher for
men probably because males are affected at an older age than
women.7 DTC is the most common solid organ malignancy in Saudi
Arabianwomen second to breast cancer.8 This fact probably renders
DTC an important and challenging disease requiring more research
and studies in this country. By and large DTC has a good outcome
and a good prognosis, as it is usually indolent and when identiﬁed
at an early stage is almost always curable On the other hand the ﬁve
year disease speciﬁc survival of patients with DTC with distant
metastases is less than 50%.9,10
2. Methods
The medical records of patients diagnosed to suffer from DTC in
the King Faisal Specialist Hospital and Research Centre Jeddah
Kingdom of Saudi Arabia between January 2000 and September
2006 were abstracted. The patients included those who were
referred from other centres (non-virgin-neck) to this tertiary care
facility and thosewhowereprimarily seen in this institution (virgin-
neck patients). This distinction ismade becausemost of the referred
patients had received initial treatment and/or an intervention been
performed in their hospitals, including surgical procedures and then
referred to our institution for further management. Both groups of
patients were managed according to a standard management
protocol made and agreed upon by the hospital’s Thyroid Cancer
Group (TCG). The TCGconsists ofmembers representing the services
which have direct involvement and interest in the management of
thyroid cancer, namely; endocrinology, surgery, radiology, nuclear
medicine, and histopathology. The protocol is applied to all patients
accordingly to which the patients’ cases are discussed during the
TCG’s weekly meeting. A dedicated team shares a common interest,
enthusiasmandperseverance that are vital to achieve andpositively
adds to the outcome and prognosis of DTC compared to other
malignancies. The current consensus-based-guidelines for the
treatment of DTC include; adequate surgery, optimization of TSH
suppression, radioactive iodine therapy, excision of residual tissue
and resection of selectedmetastases and theuse of bisphosphonates
for bonymetastases.We use a staging system derived from the Ohio
State University System, which was developed following; retro-
spective analysis of tumor registry of 1355 patients, on the basis of
a staging schemederived fromamultivariate analysis.5 According to
this system patients are classiﬁed as follows:
Stage 1 d primary tumor smaller than 1.5 cm in diameter
Stage 2 d primary tumor 1.5e4.4 cm, or presence of cervical
lymph node metastases, or more than three intra-thyroidal foci
of tumor
Stage 3 d primary tumor at least 4.5 cm or presence of extra-
thyroidal invasion
Stage 4 d distant metastases
The meetings are attended by all the concerned units. It
simultaneously serves as a teaching forum and for decision making
regarding every individual patient. The patients’ history, clinical
ﬁndings, various images and histopathology records are discussed
and their disposition is decided by consensus. The ﬁnal decision is
documented. The decision is then conveyed to the patient and his/
her family by the treating physician before he/she signs the
informed consent for treatment.
Patients are either diagnosed locally (virgin-neck patients) or had
been referred from other secondary care hospitals in the catchment
area of our centre and they would usually have been subjected tosome form of surgical treatment (Non-virgin-neck patients). These
patients would have their other investigations including the histo-
pathology slides reviewed at our centre. Other tests are requested
according to the patient’s clinical and co-morbid status, which
include complete blood count, renal proﬁle, TSH, Free T4, serum
calcium and phosphate, parathyroid hormone (PTH), thyroglobulin
and antithyroglobulin antibodies, as well as high resolution neck
ultrasonography to assess any residual thyroid tissue and/or cervical
lymph nodes. The same will be done for those patients seen
primarily at our hospital (virgin-neck) except that they will be
subjected for an ultrasound guided ﬁne needle aspiration cytology
(FNAC) for the thyroid swelling detected clinically or by ultrasound.
Non-virgin-neck patients’ treatment depends on the results of
the outside histopathology review. If it was positive for malignancy
they will have an ultrasound to look for the size of the residual
thyroid tissue and for cervical lymph nodes. Patients with residual
thyroid tissue of more than 1 cm with an elevated thyroglobulin
level will have a total body isotope scan to detect distant metas-
tases. These patients will subsequently have a remnantectomy
(excision of remnant thyroid tissue) followed one month later by
radioactive iodine therapy after hormone withdrawal. The long
term follow up of our patients is decided along the protocol
guidelines.
The data were entered in a case record form (CRF), that included
the clinical and demographic details, clinical diagnoses, presence of
co-morbid conditions, biochemical and radiological investigations.
Details of surgery(ies) performed and radioactive iodine ablation,
complications of surgery, and the ultimate outcome of patients on
subsequent follow up visits.
Statistical analysis: Data were analysed by using the Statistical
Program for Social Sciences version 12.0 (SPSS Inc. Chicago, Illinois,
USA). The appropriate measures of central tendency and variation
were used and Chi-square test was used to test independency and
t-test was used to comparemeans. P-value0.05was considered as
signiﬁcant.
3. Results
One hundred and eight medical records of patients diagnosed to
have DTC were reviewed. Seventy two patients (66.7%) were
females and 36 (33.3%) weremales. Themedian age for females was
40 years (range 14e87 years) and that for males was 45 years
(range 14e77 years). Ninety patients (83.3%) had papillary thyroid
carcinoma, four patients (3.7%) had follicular carcinoma and four-
teen patients (13%) were diagnosed with other thyroid cancers,
namely medullary, anaplastic, and thyroid lymphoma. Females
were more affected by differentiated thyroid cancer compared to
male patients, with females constitute 60.19% while males were
only 26.85% of the total number of DTC. However; there was no
statistical association between sex and type of thyroid cancer (Chi-
square ¼ 1.24; df ¼ 1; P-value ¼ 0.167) (Table 1).
The other types and number of malignant tumors of the thyroid
gland in this study includedmedullarycarcinoma(5cases), anaplastic
carcinoma (5 cases) and lymphoma (4 cases). They all together
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In this group of patients the gender distribution is equally shared at
a rate of 6.5% each.
The commonest mode of presentation was the presence of
a neck swelling in 99 patients (91.7%) the remainder had their neck
swelling discovered on ultrasound examination. Only one patient
(0.9%) in this series gave a positive family history of thyroid cancer
in a ﬁrst degree relative. A second patient (0.9%) gave a history of
exposure to radiation at an early stage of his life. Seventy patients
(68.0%) had ultrasound guided ﬁne needle aspiration cytology
(FNAC) at our hospital. The sensitivity of FNAC at our institution is
74% (95% CI 64e84%), with speciﬁcity of 94%. The other 38 patients
(32.0%) had an FNAC done in an outside facility with or without
subsequent surgical procedures, and brought histopathology slides
for review in our institution. All patients with an FNAC positive for
malignancy (51%) were subjected for surgery.
The total numbers of patients operated in our hospital were 80
patients, and the total numberoperatedelsewherewere 28patients.
Of those 80 patients, 23 patients underwent lobectomy, 21 patients
had completed thyroidectomy, 19 patients had total thyroidectomy.
The remaining 20 patients were thosewho had recurrence and they
undergo redo surgery (15 patients from outside and 5 patients who
were primarily managed at our institution). So the total number of
patients who had total thyroidectomy were 40 patients (50% of all
treated patients).
The patients who were primarily operated outside our institu-
tion and who were referred to our Centre for further treatment
were 28 patients. Of those, 14 patients had total thyroidectomy, and
8 patients had lobectomy. Of the later, 6 patients had to undergo
completion thyroidectomy in our institution. Further 11 patients
had to undergo a second operation in our institution make the total
number of the ‘non-virgin-neck patients’ 17 patients.
In the whole group, postoperative complications included
bleeding, hoarseness of voice, and transient hypocalcaemia. The
number of each complication and its percentage is shown inTable 2.
The tumor size, multi-centricity, the presence of vascular and/or
capsular invasions in DTC have a lot of bearing on the prognosis. In
addition, the rate of local recurrence and the need for adjuvant
radioactive iodine ablative therapy affect the prognosis. In our study
we found that the tumors size varies between less than 1 cm and
more than 5 cm. Of the above 80 patients operated upon in our
institution, twenty three patients had a tumor size of less than 1 cm,
22 patients’ had tumor size between 1 and 2 cm, 21 patients had
tumors between2 and5 cm, andonly 8patients their tumor sizewas
more than 5 cm, the data of the remaining six patientsweremissing.
Of those treated surgically elsewhere (n ¼ 28) before referral to our
centre, no data regarding tumor size were available to present.
From our ﬁrst group ‘Virgin-neck Group’, 14 patients had
a histology positive for vascular invasion, 28 patients had a positive
capsular invasion and 33 patients had multi-centric tumor, the
remaining 5 patients did not show features of invasiveness. Thus
patients who have overall features of histological invasiveness
represents 93% of patients treated primarily at our institution.Table 2
Documented complications following thyroid surgery for thyroid cancer patients at
the King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia,
between January 2000 & September 2006.
Complication Frequency Percentage
No complication 95 88.0%
Bleeding 2 1.8%
RLNa dysfunction 5 4.5%
Hypocalcaemia 6 3.6%
Total 108 100%
a RLND (Recurrent Laryngeal Nerve Dysfunction).The total number of patients who received adjuvant radioactive
iodine therapy (RAI) following surgery for differentiated thyroid
cancer, were 68 (63%) and 40 patients (37%) did not receive any RAI
therapy.
The main tool of follow up was a soft tissue neck ultrasound
scan, 72 (66.7%) patients had an ultrasound scanwhichwas positive
in 35 (32.4%) patients when it diagnosed a recurrence in the neck or
remnant thyroid tissue. Patients with positive ultrasound were
submitted to a diagnostic radioactive iodine whole body scan to
rule out secondary deposits. Sixty nine patients (63.9%) with
a positive radioactive iodine scan received radioactive iodine
ablation therapy.
The mean age of patients who were still alive at follow up was
41.4  17 years. In contrast, the mean age of those who died was
53  12 years. This difference in the mean age between the two
groups was not statistically signiﬁcant (t-test, p ¼ 0.185). The
overall outcome of our patient cohort is shown in Table 3.4. Discussion
This is the largest epidemiological study on thyroid cancer
performed in the western part of Saudi Arabia. The study empha-
sizes the need for a dedicated team which follows a consensus-
based protocol or a pathway for the management of DTC. Such an
approach, we believe, is very much required because DTC is
a unique and interesting disease in many aspects. Our study
conﬁrmed previous reports from Saudi Arabia and the Gulf region
about incidence and behavior of thyroid cancer. Ahmed et al.11
(1995) who presented one of the largest series in the world
showed that papillary carcinoma represents 79% of all thyroid
cancer in their series with follicular cancer accounting for 4.3% in
that series. Alzaher et al.12 (2008) reported similar ﬁgures from the
United Arab Emirates, a fact been reproduced from the review by
Alzahrani and Ravichandran13 (2007) on thyroid cancer in the Gulf
States.
There is a considerable debate and controversy about the
management of differentiated thyroid cancer in the literature.
Although most patients do well, there is still considerable conten-
tion related to the extent of thyroidectomy and the postoperative
management of these patients. There are vigorous proponents of
routine total thyroidectomy, whereas other authors recommend
less than total thyroidectomy depending on the prognostic and risk
factors.14 The existing controversy and contention inspired us to
develop the TCG consisting of members from all the disciplines
involved in the management of thyroid cancer. This consensus-
based style of management has made the challenge imposed by
managing DTC much easier, specially that there are no prospective
randomized trials of treatment been done in this area and the
results from the ongoing randomized trials will not be available for
many years, given the typically prolonged course and relative
infrequency of these tumors. Most of the information about the
treatment comes from studies of large patients’ cohorts in which
therapy has not been randomly assigned. This accounts for much of
the disagreement about managing differentiated thyroid cancer.Table 3
Overall outcome of patients with Differentiated Thyroid Cancer at the King Faisal
Specialist Hospital and Research Centre, Jeddah, Saudi Arabia, between January 2000
& September 2006.
Outcome Frequency Percentage
Alive 99 91.7%
Died 4 3.7%
Missing 5 4.6%
Total 108 100%
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properly treated by experienced physicians and surgeons as part of
a team.15 Surgery is the primary treatment of choice for patients
with DTC followed in many patients by radioactive iodine ablation
and suppressive thyroxin therapy. Established in the year 2003 the
TCG adopted a protocol of management which is a product of our
local experience and the guidelines set for the management of DTC
in adults published by the British Thyroid Association in 2002.16
The protocol provided our clinicians with universal standards of
management, applicable to the vast majority of patients with DTC.
In the majority of controversial areas (e.g. controversy of lobectomy
vs. total thyroidectomy in follicular neoplasia), one of the dilemmas
is the extent of surgical procedure in case of a cytological diagnosis
of follicular cancer. In our institution we treat them with a lobec-
tomy and isthmusectomy.
Total thyroidectomy is the standard of care in our institution for
DTC except for a unifocalmicro-papillary carcinoma (less than 1 cm)
(with no evidence of invasiveness or regional/distant spread) when
a lobectomy and an isthmusectomy would be enough without
radioactive iodine ablation. We follow the recommendations of the
ATA guidelines regarding performing central compartment lymph
node dissection in a lesion with an FNA suspicious of papillary
thyroid cancer and Hürthle cell cancers.17 However the European
consensus states that the beneﬁts of an ‘en-bloc’ central node
dissection in the absenceof pre- or intra-operativeevidence of nodal
disease is controversial. In the case of a micro-PTC, few surgeons
advocate lymph node dissection, thereby reﬂecting the positive
relationship between tumor size and lymph node metastasis.18
Lymph node invasion is recognized as a risk factor for local recur-
rence, as indicated by the large cohort study of Lundgren et al.19
(2006) which showed signiﬁcantly higher mortality rates in DTC
with lymph node involvement even after adjusting for the TNM
stage. Sywak et al.20 (2006) demonstrated that in papillary thyroid
cancer of more than 1 cm, the addition of routine lymph node
dissection of the central compartment of the neck resulted in lower
post-ablation thyroglobulin levels and higher rates of ‘athyr-
oglobulinaemia’ when compared to total thyroidectomy alone.26 In
their experience, the risk of permanent hypoparathyroidism or
recurrent laryngeal nervedysfunctionwasnotdifferentbetween the
two approaches. Similarly, in our institution, despite the fact that the
incidence of recurrent laryngeal nerve dysfunction and transient
hypocalcaemia is higher in redo surgery and in total thyroidectomy
for malignant thyroid disease, yet we have an incidence of 4.8% for
recurrent laryngeal nerve dysfunction, and 3.8% for transient
hypocalcaemia which is in line with international literature.
In our institution, when a patient has a diagnosis of follicular
neoplasmwe go for lobectomy and ismuthectomy, the ﬁnal perma-
nentpathologycomesback as follicular carcinomawe thengoback to
complete the thyroidectomy. i.e. that is to saywhen the diagnosis DT
cancer diagnosis ismade in retrospect. Remnantectomy (resection of
a remnant thyroid tissue in the thyroid bed) is carried out when
a patient has undergone total thyroidectomy and on follow upwhen
a high tyroglobulin (TGB) level is elucidated and a neck ultrasound
shows remnant thyroid tissue in the thyroidbedofmore thanonecm.
If less than 1 cm of remnant tissuewith elevated TGBwewould then
subject the patient to RAI, specially if the remnant in an anatomical
site endangering the recurrent laryngeal nerve.
We follow the American Thyroid Association (ATA) guidelines
for radioiodine ablation for patients with thyroid cancer.17 The
appropriate dose of radioactive iodine for thyroid ablation has been
a source of continuing controversy. Although the low dose radio-
active iodine ablation is advocated by some authorities,21 yet the
high ﬁxed dose of 100e200 mCi has been advocated by most
authorities.22,23 This we believe has contributed to the high overall
survival of 91.7% shown in Table 3.Comparing our centre outcome from this relatively modest
number of patients, were not different from results obtained in
centres of excellence in the developing world, with approximately
92% of our patient alive at the time of the analysis of a follow up
period of 7 years. A recent retrospective series from Italy showed
a disease free state of 94% after 48 month following surgery.24 We
seem to be ahead of other centres in the region. Bhargav et al.25
(2010) from India reported the 10 year overall survival rate of
their low and high risk patients as 80% & 54% respectively. Our
group are mostly of high risk, with signiﬁcant proportion of them
had larger tumor size, features of histological invasiveness and
evidence of locoregional spread. Our ﬁnding conﬁrms the earlier
report of Al-Nuaim et al.26 (1996) who showed that papillary
thyroid cancer in Saudi Arabia present in an advanced stage.
Regarding long term follow up it has been well documented in
the literature that most recurrences of DTC occur within the ﬁrst
ﬁve years after initial treatment, but recurrences may occur many
years or even decades later, particularly in patients with papillary
carcinoma. As most recurrences in DTC occur in the ﬁrst 5 years
after treatment,27 we adopt the approach for long term follow up
for our patients, with all patients seen at 6 monthly interval in the
ﬁrst year, then yearly following that for the ﬁrst ﬁve years, but long
term follow up is always stressed to patients.
In conclusion; our overall results, management and outcome of
DCT match what has been published from other institutions. DTC
though not a very common disease yet it is unique in its biological
behavior, prognosis and thence its management. Once the diag-
nosis of DTC is established, several treatment options may be
considered, depending upon the extent of the disease, the patient’s
age, and the presence of co-morbid conditions. In the absence of
prospective trials, conclusions regarding the optimal selection of
treatments must be based upon retrospective analyses and expert
consensus opinions augmented by consensus-based teams like our
TCG interested and dedicated to themanagement of each and every
case upon its own merits. Despite the controversy on the extent of
thyroidectomy and the limits of lymph node dissection surgery still
remains the primary mode of therapy for patients with DTC. Our
own experience highlighted in this paper is very much in accord
with this.
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